These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

414 related items for PubMed ID: 26892809

  • 1. Cellular apoptosis susceptibility (CAS) is overexpressed in thyroid carcinoma and maintains tumor cell growth: A potential link to the BRAFV600E mutation.
    Holzer K, Drucker E, Oliver S, Winkler J, Eiteneuer E, Herpel E, Breuhahn K, Singer S.
    Int J Oncol; 2016 Apr; 48(4):1679-87. PubMed ID: 26892809
    [Abstract] [Full Text] [Related]

  • 2. The expression profile of integrin receptors and osteopontin in thyroid malignancies varies depending on the tumor progression rate and presence of BRAF V600E mutation.
    Chernaya G, Mikhno N, Khabalova T, Svyatchenko S, Mostovich L, Shevchenko S, Gulyaeva L.
    Surg Oncol; 2018 Dec; 27(4):702-708. PubMed ID: 30449496
    [Abstract] [Full Text] [Related]

  • 3. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation.
    Huang Y, Liao D, Pan L, Ye R, Li X, Wang S, Ye C, Chen L.
    Eur J Endocrinol; 2013 May; 168(5):675-81. PubMed ID: 23416953
    [Abstract] [Full Text] [Related]

  • 4. BRAFV600E mutation and X-linked inhibitor of apoptosis expression in papillary thyroid carcinoma.
    Gu LQ, Li FY, Zhao L, Liu Y, Zang XX, Wang TX, Chen HP, Ning G, Zhao YJ.
    Thyroid; 2009 Apr; 19(4):347-54. PubMed ID: 19355825
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.
    Duquette M, Sadow PM, Husain A, Sims JN, Antonello ZA, Fischer AH, Song C, Castellanos-Rizaldos E, Makrigiorgos GM, Kurebayashi J, Nose V, Van Hummelen P, Bronson RT, Vinco M, Giordano TJ, Dias-Santagata D, Pandolfi PP, Nucera C.
    Oncotarget; 2015 Dec 15; 6(40):42445-67. PubMed ID: 26636651
    [Abstract] [Full Text] [Related]

  • 7. Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness.
    Zhang T, Shen X, Liu R, Zhu G, Bishop J, Xing M.
    Oncotarget; 2017 Jan 03; 8(1):900-914. PubMed ID: 27863429
    [Abstract] [Full Text] [Related]

  • 8. Targeting BRAFV600E in thyroid carcinoma: therapeutic implications.
    Mitsiades CS, Negri J, McMullan C, McMillin DW, Sozopoulos E, Fanourakis G, Voutsinas G, Tseleni-Balafouta S, Poulaki V, Batt D, Mitsiades N.
    Mol Cancer Ther; 2007 Mar 03; 6(3):1070-8. PubMed ID: 17363500
    [Abstract] [Full Text] [Related]

  • 9. Up-regulation of urinary-type plasminogen activator correlates with high-risk papillary thyroid carcinoma with BRAF(V600E) mutation and its possible molecular mechanism.
    Wakasa T, Li Y, Bai Y, Liu Z, Ozaki T, Mori I, Miyauchi A, Kakudo K, Nakamura M.
    Pathol Res Pract; 2014 Nov 03; 210(11):733-8. PubMed ID: 25085839
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Clinicopathologic features and BRAF(V600E) mutation analysis in cutaneous metastases from well-differentiated thyroid carcinomas.
    Erickson LA, Jin L, Nakamura N, Bridges AG, Markovic SN, Lloyd RV.
    Cancer; 2007 May 15; 109(10):1965-71. PubMed ID: 17387744
    [Abstract] [Full Text] [Related]

  • 12. Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma.
    Baitei EY, Zou M, Al-Mohanna F, Collison K, Alzahrani AS, Farid NR, Meyer B, Shi Y.
    J Pathol; 2009 Apr 15; 217(5):707-15. PubMed ID: 19156774
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse.
    Renaud F, Gnemmi V, Devos P, Aubert S, Crépin M, Coppin L, Ramdane N, Bouchindhomme B, d'Herbomez M, Van Seuningen I, Do Cao C, Pattou F, Carnaille B, Pigny P, Wémeau JL, Leteurtre E.
    Thyroid; 2014 Sep 15; 24(9):1375-84. PubMed ID: 25012490
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Upregulation of endocrine gland-derived vascular endothelial growth factor in papillary thyroid cancers displaying infiltrative patterns, lymph node metastases, and BRAF mutation.
    Pasquali D, Santoro A, Bufo P, Conzo G, Deery WJ, Renzullo A, Accardo G, Sacco V, Bellastella A, Pannone G.
    Thyroid; 2011 Apr 15; 21(4):391-9. PubMed ID: 21385081
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. MicroRNA-150-5p affects cell proliferation, apoptosis, and EMT by regulation of the BRAFV600E mutation in papillary thyroid cancer cells.
    Yan R, Yang T, Zhai H, Zhou Z, Gao L, Li Y.
    J Cell Biochem; 2018 Nov 15; 119(11):8763-8772. PubMed ID: 30126001
    [Abstract] [Full Text] [Related]

  • 19. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.
    Riesco-Eizaguirre G, Rodríguez I, De la Vieja A, Costamagna E, Carrasco N, Nistal M, Santisteban P.
    Cancer Res; 2009 Nov 01; 69(21):8317-25. PubMed ID: 19861538
    [Abstract] [Full Text] [Related]

  • 20. BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid <or=1 cm and their paired lymph node metastases.
    Rodolico V, Cabibi D, Pizzolanti G, Richiusa P, Gebbia N, Martorana A, Russo A, Amato MC, Galluzzo A, Giordano C.
    Cancer; 2007 Sep 15; 110(6):1218-26. PubMed ID: 17685465
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.